Aligos Therapeutics - 5.08% Drop in 24 Hours Amid Stock Option Grants and Pipeline Updates

On DEC 12 2025, Aligos Therapeutics (NASDAQ: ALGS, “Aligos”) saw its stock price drop by 5.08% within 24 hours to reach $0.1235, marking a 7.37% decline over seven days and a 9.81% drop over one month. Over the past year, the stock has fallen by 63.17%. These price movements come amid several key corporate announcements related to equity compensation and recent clinical development updates.

Inducement Grants for New Hires

On December 9, 2025, Aligos Therapeutics announced the grant of non-qualified stock options under its 2024 Inducement Plan to newly hired employees. A total of 14,100 shares were allocated as part of the inducement grant, issued at the closing price of the company’s stock on the grant date. The equity awards are designed to incentivize new talent and are aligned with the Nasdaq Listing Rule 5635(c)(4), which allows such grants for newly hired employees.

The vesting schedule is structured to vest 25% of the shares on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter, subject to continued employment. These grants are part of Aligos’ broader strategy to attract and retain skilled personnel in its R&D and clinical development teams.

Recent Scientific Presentations and Pipeline Highlights

Aligos continued to showcase its pipeline advancements at key scientific meetings. On December 11, 2025, the company presented positive data at the HEP-DART 2025 conference, focusing on its research in chronic hepatitis B virus (HBV) infection, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). These updates reinforce Aligos’ commitment to addressing high unmet medical needs through its science-driven development approach.

Earlier in November, Aligos also presented findings at The Liver Meeting® 2025, further expanding the visibility of its therapeutic candidates. These presentations are critical for maintaining stakeholder confidence and supporting ongoing R&D initiatives across its therapeutic areas.

Corporate Governance and Strategic Direction

Aligos is a clinical stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases. The company’s mission centers on leveraging its deep R&D expertise to deliver innovative treatments to patients. While the recent stock price decline may reflect broader market sentiment or sector-specific dynamics, the company remains focused on its long-term objectives.

The Compensation Committee’s decision to issue inducement grants highlights the company’s strategic emphasis on talent acquisition and retention as it advances its pipeline toward clinical and regulatory milestones.

The company’s forward-looking statements emphasize its dedication to advancing research and development, though such efforts are subject to inherent risks, including the drug development process, regulatory hurdles, and market conditions. Investors are encouraged to review Aligos’ recent filings and public disclosures for a comprehensive understanding of its current status and future plans.